Eyepoint Pharmaceuticals (EYPT) USD0.01

Sell:$14.00Buy:$14.70$0.83 (6.06%)

Prices delayed by at least 15 minutes
Sell:$14.00
Buy:$14.70
Change:$0.83 (6.06%)
Deal now
Prices delayed by at least 15 minutes
Sell:$14.00
Buy:$14.70
Change:$0.83 (6.06%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E. DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD). Additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The Company’s other products include YUTIQ and DEXYCU.

Objective

Key people

Jay S. Duker
President, Chief Executive Officer, Director
Nancy S. Lurker
Executive Vice Chairman of the Board
George Elston
Chief Financial Officer, Executive Vice President
Ramiro Ribeiro
Chief Medical Officer
Goeran A. Ando
Non-Executive Independent Chairman of the Board
Wendy F. Dicicco
Non-Executive Independent Director
Stuart Duty
Non-Executive Independent Director
Fred Hassan
Non-Executive Independent Director
John B. Landis
Non-Executive Independent Director
Click to see more

Key facts

  • Shares in issue
    82.79m
  • EPIC
    EYPT
  • ISIN
    US30233G2093
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • Market cap
    $1.13bn
  • Employees
    165
  • Exchange
    NASDAQ
  • Index
    TR Equity United States Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.